Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMA on health claims

This article was originally published in The Tan Sheet

Executive Summary

American Medical Association "strongly opposes" FDA's decision to "allow a lower standard - the so-called weight of the scientific evidence standard - to be used in deciding whether a health claim can be placed on the labeling of a conventional food product," according to Feb. 21 comments. The "weight of the scientific evidence standard" would allow the use of health claims "that have a reasonable chance of being erroneous" and "actually could confuse consumers" rather than help them to make informed decisions, the medical group contends. Comments respond to FDA's decision to no longer hold health claims for food, supplements to significant scientific agreement standard (1"The Tan Sheet" Dec. 23, 2002, p. 10). AMA also says it is working with Congress to modify DSHEA...

You may also be interested in...



Qualified Health Claims “Reasonable Consumer” Standard Adopted By FDA

FDA will employ a "reasonable consumer" standard, rather than an "ignorant, unthinking and credulous" consumer standard, to determine whether dietary supplement and food labeling is misleading, the agency announced Dec. 18

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel